

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/46, 31/66</b>		<b>A1</b>	(11) International Publication Number: <b>WO 97/44017</b> (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: <b>PCT/US97/08055</b> (22) International Filing Date: 13 May 1997 (13.05.97) (30) Priority Data: 60/017,881 17 May 1996 (17.05.96) US 9613183.4 24 June 1996 (24.06.96) GB (71) Applicant (for all designated States except US): <b>MERCK &amp; CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</b> (72) Inventors; and (75) Inventors/Applicants (for US only): <b>KATDARE, Ashok, V. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). KRAMER, Kenneth, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). GARDNER, Colin, R. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</b> (74) Common Representative: <b>MERCK &amp; CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).</b>			(81) Designated States: <b>AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <i>With international search report.</i>
(54) Title: <b>EFFERVESCENT BISPHOSPHONATE FORMULATION</b>			
(57) Abstract  An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and, optionally, flavoring agents, colorants and sweeteners.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**TITLE OF THE INVENTION**  
**EFFERVESCENT BISPHOSPHONATE FORMULATION**

**CROSS-REFERENCE TO RELATED APPLICATIONS**

5                   Not Applicable

**STATEMENT REGARDING FEDERALLY-SPONSORED R&D**  
Not Applicable

10   **REFERENCE TO MICROFICHE APPENDIX**  
Not Applicable

**FIELD OF THE INVENTION**

15               This invention relates to pharmaceutical effervescent  
formulations of bisphosphonates, especially alendronate, and in  
particular, tablets and powders which effervesce when added to water.

**BACKGROUND OF THE INVENTION**

20               There are numerous bisphosphonates which have been  
identified as having utility as pharmaceutical agents which inhibit bone  
resorption. These include:

alendronate-- (4-amino-1-hydroxy-butylidene)bis-phosphonate;  
cimadronate-- [(cycloheptylamino)methylene]bis-phosphonate;  
clodronate-- (dichloromethylene)-bis-phosphonate;  
25   EB-1053-- [1-hydroxy-3-(1-pyrrolidinyl)-propylidene]bis-  
phosphonate;  
etidronate-- (1-hydroxyethylidene)-bis-phosphonate;  
ibandronate-- [1-hydroxy-3-(methylpentylamino)propylidene]bis-  
phosphonate;  
30   neridronate-- (6-amino-1-hydroxyhexylidene)bis-phosphonate;  
olpadronate-- [3-(dimethylamino)-1-hydroxy-propylidene]bis-  
phosphonate;  
pamidronate-- (3-amino-1-hydroxypropylidene)bis-phosphonate;  
risedronate-- [1-hydroxy-2-(3-pyridinyl)-ethylidene]bis-  
35   phosphonate;

tiludronate-- [[(4-chlorophenyl)thio]methylene]bis-phosphonate  
YH 529-- [1-hydroxy-2-imidazo-(1,2a)pyridin-3-ylethylidene]bis-  
phosphonate; and  
zoledronate-- [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-  
phosphonate.

Alendronate has been approved by various regulatory agencies, including the Food and Drug Administration in the United States as an oral osteoporosis treatment in post menopausal women. The currently marketed formulation is a tablet, and the patient is instructed to take the tablet with a full glass of water in the morning, at least a half hour prior to eating or drinking. However, certain side effects, including esophageal irritation and erosion have been reported if the tablet was not taken with enough water, or if the patient did not remain in an upright position for approximately one-half hour after taking the medication.

It would be desirable to develop a formulation which allows a bisphosphonate to be taken orally, yet avoids problems associated with prolonged contact between the medication and the esophagus.

## SUMMARY OF THE INVENTION

Not Applicable

## BRIEF DESCRIPTION OF THE DRAWINGS

Not Applicable

## DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to an effervescent pharmaceutical formulation comprising, as an active ingredient, a bisphosphonate selected from the group consisting of: alendronate, cimadronate, clodronate, EB-1053, etidronate, ibandronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, YH 529, zoledronate, pharmaceutically acceptable salts and esters of the foregoing, and mixtures of the foregoing;

an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts;

a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;

a binder selected from the group consisting of a non-reducing sugar such as mannitol, lactose, dextrose or sorbitol; polyvinyl pyrrolidone, or, sodium chloride, sodium benzoate and sodium sulfate;

a lubricant selected from the group consisting of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and polyethylene glycol (PEG); and

optionally, one or more additional agents selected from the group consisting of flavoring agents (such as orange and cherry) colorants, and sweeteners (including xylitol, aspartame or acesulfame K).

The present invention is also directed to an effervescent pharmaceutical formulation comprising alendronate or a pharmaceutically acceptable salt thereof as an active ingredient and

an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts;

a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;

wherein the acid source is present in at least an equivalent amount relative to the source of carbonate;

a binder selected from the group consisting of mannitol, sorbitol, polyvinyl pyrrolidone, lactose, sodium chloride sodium benzoate and sodium sulfate;

5 a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate, powdered sodium bicarbonate and polyethylene glycol (PEG); and optionally, one or more additional agents selected from the group consisting of flavoring agents, particularly orange and cherry colorants, and sweeteners selected from the group consisting of xylitol,  
10 aspartame and acesulfame K.

The effervescent pharmaceutical formulation of the present invention may be either a tablet or a powder. To use the formulation, the tablet or powders are placed in an convenient amount of water to produce an effervescent liquid, and the patient drinks the effervescent liquid.

15 In one embodiment the formulation is a tablet, wherein in one class the total weight of the tablet ranges from about 100 to about 50,000 mg. In another embodiment, the tablet weight ranges from about 1500 to about 32,500 mg and more particularly from about 20,800 to about 30,150 mg.

20 As used throughout this specification and claims, the term "bisphosphonate" is intended to include the related bisphosphonic acids and salts, and various crystalline and amorphous forms. "Alendronate" includes the related bisphosphonic acid, and salt forms. It includes crystalline, hydrated crystalline, and amorphous forms of alendronate. It  
25 specifically includes alendronate sodium and alendronate monosodium trihydrate.

Methods for the preparation of bisphosphonates are well known in the art. Methods for the preparation of alendronate and alendronate sodium salt trihydrate are known. In particular, methods for  
30 the preparation of alendronate may be found in U.S. patents 4,922,007, 5,019,651 and 5,510,517, each of which is hereby incorporated by reference. The amount of active in the formulation based on a weight of alendronate will range from 1 to 80 mg, particularly 5-40 mg and more



particularly 5-15 mg. Exemplary amounts of alendronate are 5, 10 and 40 mg.

The formulations of this invention have many distinct advantages. First of all, the patients drinks an effervescent liquid, which  
5 limits the amount of time in which the bisphosphonate is in contact with the esophageal tissue, thus minimizing the risk of irritation. Secondly, the bioavailability of at least some of the bishosphonates, including alendronate is increased as a consequence of an excipient acting as a sequestering agent. Thirdly, the alendronate formulations are particularly  
10 advantageous in that alendronate is often prescribed to elderly patients who may experience difficulty in swallowing pills, but can more easily swallow a liquid formulation.

In preferred embodiments of the invention the acid source is chosen from acid sources which are also sequestering agents. This is an  
15 important consideration because bisphosphonates, particularly alendronate, can be a potent sequestering agent of divalent cations, especially  $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ . If either of these cations are present, the alendronate will sequester them, rendering the alendronate less bioavailable. Preferred acid sources which also act as a sequestering  
20 agent include citric acid and tartaric acid, and mixtures thereof. The excess citric acid or tartaric acid in the formulation binds the ions in issue and prevents their complexation with alendronate.

The carbonate source should be chosen so that it does not contain divalent cations which could be sequestered by the  
25 bisphosphonate. Suitable carbonate sources are sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate and sodium glycine carbonate. Preferred carbonate sources are sodium bicarbonate, sodium carbonate, and mixtures thereof.

In one aspect of this invention the acid source is present in  
30 an amount equal or greater than the carbonate source, on a molecular equivalent basis. Thus, when citric acid is the acid source and sodium bicarbonate is the carbonate source, the mole ratio of citric acid/bicarbonate is at least 1:3. In a particular class of this aspect there is an excess of citric acid, as this not only helps to efficiently generate the

effervescence, but also acts to sequester any ions which might otherwise complex with alendronate and the excess also acts as a flavor enhancer.

In an illustration of the excess acid source, the mole ratio of citric acid to bicarbonate ranges from 1:1 to 3:1. Where sodium carbonate is used as the source of carbonate an equal equivalent with citric acid will require a mole ratio of 2 moles citric acid to 3 moles carbonate. Analogous ratios can be calculated for any source of acid and carbonate, and of course the carbonate source may be present as a mixture of bicarbonate and carbonate.

For patients who exhibit gastric irritation another aspect of this invention is to employ excess amounts of the carbonate source to provide an antacid effect to the formulation. Example 2 below demonstrates such a formulation.

The binder may be a non-reducing sugar, such as mannitol, compressible lactose, dextrose or sorbitol. Alternatively, a polymer such as polyvinylpyrrolidone may be used. Other binders can include sodium chloride, sodium benzoate and sodium sulfate. The binder is usually present in approximately 3-10% of the tablet, and preferably about 5% (based on wt/wt), e.g. if the tablet weighs 1000 mg, the binder will be from about 30-100 mg, more preferably about 50 mg. If, however, a direct compression process is used to make the tablets, then a higher amount of binder is employed, preferably about 300-400 mg.

The tablet should also contain a lubricant, which typically comprises about 0.5 to about 5% of the tablet on a wt/wt basis, and preferably about 1%. Preferred lubricants include powdered sodium benzoate, micronized polyethylene glycol 6000 and polyethylene glycol 8000, sodium lauryl sulfate, powdered sodium bicarbonate and L-leucine.

For effervescent powder formulations, the composition of the powder is similar to that of the tablet, except that the lubricant is generally present in a lesser amount (about less than one-half that in the tablet) and the binder should be chosen so that it is a dry binder. In preferred formulations, the powder is granulated.

Where desired a colorant, flavoring agent such as orange or cherry or sweetner from the group xylitol, aspartame, or acesulfame K

may be added to the formulation. Various methodologies for preparing the formulations of the current invention are illustrated in the examples below.

The following formulations and manufacturing procedures  
5 can be used for manufacture of effervescent tablets containing alendronate sodium.

It should be understood that one skilled in this art will recognize equivalent formulations which are intended to be included with the scope of this invention.

10

### EXAMPLE 1

	Alendronate sodium (in mg alendronate acid)	5-10	10 mg
15	Citric acid, anhydrous (granular)	600-700	650 mg
	Sodium bicarbonate (granular)	300-500	367 mg
	Sodium carbonate, anhydrous	20-60	40 mg
	Flavoring agent (optional)	10-50	25 mg
	Colorant (optional)	0-10	5 mg
20	Sodium benzoate	5-15	7.5 mg
	Water	0-5	2 mg.

Premix sodium benzoate with sodium bicarbonate and alendronate sodium. Mix color with sodium carbonate. Place citric acid  
25 in a bowl of a suitable blender. Add the 2 mg water to the citric acid slowly and mix thoroughly to form a moist blend. Add to the blend, in sequence, while mixing, the sodium bicarbonate mix, and the sodium carbonate-color mix until uniformly distributed. Compress tablets using suitable size tooling. Cure the tablets, cool and package in aluminum  
30 foil.

EXAMPLE 2

	Alendronate sodium (in mg alendronate acid)	5-10	5 mg or 10 mg
5	Citric acid, anhydrous (granular)	450-650	590 mg
	Sodium bicarbonate (granular)	750-1000	850 mg
	Sodium bicarbonate, powder	50-150	87 mg
	Citrus flavor (optional)	0-50	25 mg
	Water	0-25	15 mg.

Blend alendronate sodium, citric acid and citrus flavor in a suitable blender. Quickly add all of water and mix until a workable mass is formed. Granulate through a suitable screen using a granulator. Spread evenly on a paper-lined tray or a fluid bed dryer. Place a dried granulation in a suitable blender and add powder sodium bicarbonate. Mix well. Compress tablets using a suitable flat face beveled edge tooling. Package in aluminum foil or aluminum tubes.

EXAMPLE 3

	Alendronate sodium (in mg alendronate acid)	10 mg
	Mannitol, direct compression grade	165 mg
25	Sodium bicarbonate	850 mg
	Citric acid	530 mg
	Sodium benzoate	15 mg

Mix alendronate sodium and sodium benzoate in a suitable mixer. Add mannitol and continue mixing till uniform. Add sequentially citric acid and sodium bicarbonate. Roller compact the powder mix followed by granulation using a suitable screen. Compress the granulation using a suitable tooling. Package the tablets in aluminum foil.

EXAMPLE 4

	Alendronate sodium (in mg alendronate acid)	2.5-10	10 mg
5	Citric acid, anhydrous (granular)	400-800	600 mg
	Sodium bicarbonate (granular)	1000-2000	1500 mg
	Sodium carbonate, anhydrous	20-80	40 mg
	Flavoring agent (optional)	0-50	25 mg
	Colorant (optional)	0-15	5 mg
10	Sodium benzoate	25-175	150 mg
	Xylitol	100-300	200 mg
	Sweetner (aspartame)	1-10	2.5 mg

Part 1. Blend in a suitable mixer xylitol, alendronate and  
15 400 mg sodium bicarbonate. Roller compact this mixture.

Part 2. Blend in a suitable mixer sodium benzoate, citric acid, 900 mg sodium bicarbonate, color, flavor and sweetner; then roller compact this mixture.

Part 3. Granulate Parts 1 and 2 through a suitable screen,  
20 add remaining powders and mix.

Compress the granulation using a suitable tooling. Package the tablets in aluminum foil.

## WHAT IS CLAIMED IS:

1. An effervescent pharmaceutical formulation comprising as an active ingredient a bisphosphonate selected from the groups consisting of: alendronate, cimadronate, clodronate, EB-1053, etidronate, ibandronate, neridronate, olpadronate, pamidronate, risedronate, tiludronate, YH 529, zoledronate, pharmaceutically acceptable salts and esters of the foregoing, and mixtures of the foregoing;  
and  
an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts; a carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;  
a binder selected from the group consisting of a non-reducing sugar, polyvinyl pyrrolidone, sodium chloride, sodium benzoate and sodium sulfate;  
a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and PEG; and  
optionally, one or more additional agents selected from the group consisting of flavoring agents, colorants, and sweeteners.
2. An effervescent pharmaceutical formulation according to Claim 1 wherein the active ingredient comprises alendronate or a pharmaceutically acceptable salt thereof as an active ingredient and further comprising:

- an acid source selected from the group consisting of: citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid; an anhydride of said acids; an acid salt selected from the group consisting of sodium dihydrogen phosphate, disodium dihydrogen pyrophosphate and sodium acid sulfite; and mixtures of the acids, anhydrides and acid salts; a  
5 carbonate source selected from the group consisting of: sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, sodium sesquicarbonate, sodium glycine carbonate, and mixtures thereof;
- 10 wherein the acid source is present in an equal or excess amount compared to the carbonate source, based on molecular equivalent amounts;
- a binder selected from the group consisting of mannitol, sorbitol, polyvinyl pyrrolidone, lactose, sodium chloride, sodium  
15 benzoate and sodium sulfate;
- a lubricant selected from the group consist of stearic acid salts, powdered sodium benzoate, L-leucine, sodium laurel sulfate and PEG; and
- 20 optionally, one or more additional agents selected from the group consisting of flavoring agents, colorants, and sweeteners.
3. A formulation according to Claim 2 wherein the amount of alendronate or salt thereof is from 1-80 mg.
- 25 4. A formulation according to Claim 3 wherein the acid source is citric acid, tartaric acid or mixtures thereof.
5. A formulation according to Claim 3 wherein the carbonate source is sodium bicarbonate, sodium carbonate, and mixtures  
30 thereof.
6. A formulation according to Claim 5 wherein the mole ratio of citric acid to bicarbonate is from 1:1 to 1:3.

7. A formulation according to Claim 5 wherein the binder is mannitol, lactose, dextrose or sorbitol.

8. A formulation comprising (in mg):

5	Alendronate sodium (in mg alendronic acid)	5-10 mg
	citric acid	600-750
	sodium bicarbonate	300-500
	sodium carbonate	20-60
10	sodium benzoate	5-15
	water	0-5.

9. A formulation according to Claim 8, further comprising a flavoring agent or a colorant.

15

10. A formulation comprising (in mg):

	Alendronate sodium (in mg alendronic acid)	5-10
	citric acid	450-650
20	sodium bicarbonate (total)	800-1150.

11. A formulation comprising (in mg):

	Alendronate sodium (in mg alendronic acid)	2.5-10
25	citric acid	400-800
	sodium bicarbonate	1000-2000
	sodium carbonate	20-80
	sodium benzoate	25-175
	xylitol	100-300.

30



## 12. A formulation made by the process of combining:

	Alendronate sodium	
	(in mg alendronic acid)	2.5-10
	citric acid	400-800
5	sodium bicarbonate	1000-2000
	sodium carbonate	20-80
	sodium benzoate	25-175
	xylitol	100-300.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/08055

A. CLASSIFICATION OF SUBJECT MATTER  
 IPC 6 A61K9/46 A61K31/66

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 2 153 225 A (GENTILI IST SPA) 21 August 1985 see the whole document	1-6
Y	---	7-12
Y	US 4 621 077 A (ROSINI SERGIO ET AL) 4 November 1986 see column 13, line 15 - line 25	1-12
Y	---	1-12
Y	WO 94 14455 A (MERCK & CO INC ;WHITEFORD DONNA T (US)) 7 July 1994 see page 11, line 1 - line 15	1-12
Y	---	1-12
Y	EP 0 521 388 A (GERGELY GERHARD) 7 January 1993 see column 6, line 39 - column 9, line 43; claim 10	1-12
	---	
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

22 July 1997

Date of mailing of the international search report

12.08.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+ 31-70) 340-3016

Authorized officer

Seegert, K

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 97/08055

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 93 11774 A (MERCK & CO, INC) 24 June 1993 see page 18, line 18 - page 19, line 10 ---	1-12
P,X	WO 96 41618 A (SANOFI WINTHROP INC) 27 December 1996 see page 12, line 32 - page 13, line 20 -----	1,4,5
P,Y		2,3,6-12

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/08055

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 2153225 A	21-08-85	DE 3500670 A FR 2558060 A	18-07-85 19-07-85
US 4621077 A	04-11-86	BE 896453 A CH 661437 A DE 3313049 A FR 2525223 A GB 2118042 A,B HK 79390 A JP 1589937 C JP 2013645 B JP 58189193 A LU 84746 A LU 88714 A NL 8301324 A,B SE 463239 B SE 8302130 A	01-08-83 31-07-87 17-11-83 21-10-83 26-10-83 12-10-90 30-11-90 04-04-90 04-11-83 17-11-83 23-08-96 01-11-83 29-10-90 16-10-83
WO 9414455 A	07-07-94	AU 5953894 A CA 2151240 A EP 0675723 A JP 8505142 T	19-07-94 07-07-94 11-10-95 04-06-96
EP 0521388 A	07-01-93	AT 122228 T CA 2072533 A DE 59202126 D ES 2074769 T JP 5186332 A US 5393531 A	15-05-95 02-01-93 14-06-95 16-09-95 27-07-93 28-02-95
WO 9311774 A	24-06-93	US 5270365 A AT 150646 T AU 675417 B AU 3242093 A CA 2122498 A CZ 9401487 A DE 69218624 D EP 0617624 A ES 2100519 T HU 68788 A	14-12-93 15-04-97 06-02-97 19-07-93 24-06-93 15-03-95 30-04-97 05-10-94 16-06-97 28-07-95

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 97/08055

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9311774 A		IL 104109 A	18-02-97
		JP 7502506 T	16-03-95
		NO 942267 A	16-06-94
		NZ 246274 A	24-02-97
		SK 72794 A	12-04-95
		ZA 9209712 A	14-06-93
<hr/>			
WO 9641618 A	27-12-96	AU 5980896 A	09-01-97
<hr/>			

**THIS PAGE BLANK (USPTO)**